Selected article for: "BIS group and MONT group"
Author: Kim, Chang-Keun; Callaway, Zak; Park, Jin-Sung; Nishimori, Hisashi; Ogino, Tikatoshi; Nagao, Mizuho; Fujisawa, Takao
Title: Montelukast Reduces Serum Levels of Eosinophil-Derived Neurotoxin in Preschool Asthma
  • Document date: 2018_8_30
    • ID: uzge50xu_16
    Snippet: A secondary outcome of this study was to compare changes in sEDN in all patients with sEDN ≥ 53 ng/mL and HDM sensitivity (BIS and MONT groups) and in those patients whose sEDN was < 53 ng/mL, were not sensitive to HDM or both (OBS group). Serum was taken from each patient at −2 weeks, sEDN was measured, and then this value was used at 0 week (termed "Pre") to randomize each patient into either the BIS or the MONT group. Also, sEDN was measur.....
    Document: A secondary outcome of this study was to compare changes in sEDN in all patients with sEDN ≥ 53 ng/mL and HDM sensitivity (BIS and MONT groups) and in those patients whose sEDN was < 53 ng/mL, were not sensitive to HDM or both (OBS group). Serum was taken from each patient at −2 weeks, sEDN was measured, and then this value was used at 0 week (termed "Pre") to randomize each patient into either the BIS or the MONT group. Also, sEDN was measured at 12 weeks (termed "Post"). "Pre" and "Post" sEDN levels were then compared in each patient using the Wilcoxon matched-pairs signed rank test.

    Search related documents:
    Co phrase search for related documents
    • MONT group and study secondary outcome: 1, 2
    • MONT group bis and sEDN Post pre: 1, 2
    • MONT group bis and study secondary outcome: 1, 2
    • Post pre and sEDN Post pre: 1, 2
    • Post pre and sign rank test: 1, 2
    • Post pre and study secondary outcome: 1, 2
    • rank test and sEDN Post pre: 1
    • rank test and sign rank test: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • secondary outcome and study secondary outcome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25